Albireo Overview
- Year Founded
-
2008

- Status
-
Acquired/Merged
- Employees
-
130

- Latest Deal Type
-
M&A
- Financing Rounds
-
6
- Investments
-
1
Albireo General Information
Description
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.
Contact Information
Website
www.albireopharma.comCorporate Office
- 53 State Street
- 19th Floor
- Boston, MA 02109
- United States
Corporate Office
- 53 State Street
- 19th Floor
- Boston, MA 02109
- United States
Albireo Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Albireo Comparisons
Industry
Financing
Details
Albireo Competitors (19)
One of Albireo’s 19 competitors is Phathom Pharmaceuticals, a Formerly VC-backed company based in Florham Park, NJ.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Phathom Pharmaceuticals | Formerly VC-backed | Florham Park, NJ | ||||
Aldeyra Therapeutics | Formerly VC-backed | Lexington, MA | ||||
Voyager Therapeutics | Corporation | Lexington, MA | ||||
Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA |
Albireo Patents
Albireo Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2023390975-A1 | Asbt inhibitors in the treatment of renal diseases | Pending | 09-Dec-2022 | ||
US-20240207286-A1 | Asbt inhibitors in the treatment of renal diseases | Pending | 09-Dec-2022 | ||
AU-2023390972-A1 | Cocrystals of odevixibat | Pending | 09-Dec-2022 | ||
AU-2023374724-A1 | Treating alagille syndrome (algs) | Pending | 03-Nov-2022 | ||
US-20240173333-A1 | Treating alagille syndrome (algs) | Pending | 03-Nov-2022 | A61K31/554 |
Albireo Signals
Albireo Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Albireo Acquisitions (1)
Albireo’s most recent deal was a Merger/Acquisition with Biodel for . The deal was made on 03-Nov-2016.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Biodel | 03-Nov-2016 | Merger/Acquisition | Pharmaceuticals |
Albireo FAQs
-
When was Albireo founded?
Albireo was founded in 2008.
-
Where is Albireo headquartered?
Albireo is headquartered in Boston, MA.
-
What is the size of Albireo?
Albireo has 130 total employees.
-
What industry is Albireo in?
Albireo’s primary industry is Biotechnology.
-
Is Albireo a private or public company?
Albireo is a Private company.
-
What is the current valuation of Albireo?
The current valuation of Albireo is
. -
What is Albireo’s current revenue?
The current revenue for Albireo is
. -
How much funding has Albireo raised over time?
Albireo has raised $102M.
-
Who are Albireo’s investors?
Aberdeen Asset Management, Biodel, Decheng Capital, HBM Healthcare Investments, and Kreos Capital are 5 of 11 investors who have invested in Albireo.
-
Who are Albireo’s competitors?
Phathom Pharmaceuticals, Aldeyra Therapeutics, Voyager Therapeutics, Minerva Neurosciences, and ACADIA Pharmaceuticals are some of the 19 competitors of Albireo.
-
When was Albireo acquired?
Albireo was acquired on 02-Mar-2023.
-
Who acquired Albireo?
Albireo was acquired by Ipsen (Pharmaceuticals).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »